TASER International's (NASDAQ: TASR ) eponymous stun guns continue to rake in sales. On Tuesday, the Scottsdale, Ariz.-based weapons maker announced four orders of significant size, and several more of smaller orders of magnitude. The big four sales reported today included:
500 TASER X26 "Conducted Electrical Weapons" sold to the U.S. Army. 200 X26Ps sold to the Manatee County Sheriff's Department in Florida. 166 TASER X2s sold to the Charles County Sheriff's Office in Maryland. 100 more X2s sold to the Toledo Police Department in Ohio.Additional sales of X2s, X26Ps, and TASER CAM HDs -- presumably orders of smaller size than the smallest figures broken out individually by TASER -- were booked to customers in California, Colorado, Illinois, Louisiana, Nevada, New Jersey, Ohio, Oregon, Rhode Island, Tennessee, and Texas -- and certain unnamed "international customers" as well.
Financial details of the sales were not disclosed, but at advertised list prices (for those products for which prices are listed), the sum total of the above-listed orders appears to exceed $1.1 million.
Top 10 Growth Companies To Invest In 2015: Euronet Worldwide Inc.(EEFT)
Euronet Worldwide, Inc. provides payment and transaction processing and distribution solutions to financial institutions, retailers, service providers, and individual consumers. The company operates in three segments: EFT Processing, epay, and Money Transfer. The EFT Processing segment provides electronic payment solutions consisting of automated teller machine (ATM) network participation, outsourced ATM and point-of-sale (POS) management solutions, credit and debit card outsourcing, card issuing, and merchant acquiring services; advertising, customer relationship management, currency conversion, mobile top-up, bill payment, fraud management, and foreign remittance payout services; and integrated software solutions for electronic payments and transaction delivery systems. As of December 31, 2011, it processed transactions for a network of 14,224 ATMs and approximately 57,000 POS terminals in Europe, the Middle East, and the Asia Pacific. The epay segment engages in the ele ctronic distribution of prepaid mobile airtime and other electronic payment products, and provides collection services for various payment products, cards, and services. This segment operates a network of approximately 615,000 POS terminals to enable electronic processing of prepaid mobile airtime top-up services and other electronic payment products in Europe, the Middle East, the Asia Pacific, North America, and South America, as well as distributes vouchers and physical gifts in Europe. The Money Transfer segment provides consumer-to-consumer money transfer services through a network of sending agents and company-owned stores in North America and Europe; customers bill payment services; payment alternatives, such as money orders and prepaid debit cards; check cashing services for various issued checks; and foreign currency exchange services. The company serves customers in approximately 150 countries worldwide. Euronet Worldwide, Inc. was founded in 1994 and is headquarte red in Leawood, Kansas.
Advisors' Opinion:- [By John Udovich]
Small cap money transfer stock Euronet Worldwide, Inc (NASDAQ: EEFT) and Wal-Mart Stores, Inc (NYSE: WMT) have announced an exclusive money transfer service called "Walmart-2-Walmart,��meaning its time to take a closer look at the stock along with the performance of peers like Moneygram International Inc (NASDAQ: MGI), Xoom Corp (NASDAQ: XOOM) and The Western Union Company (NYSE: WU) which fell 17.68%, 4.32% and 4.98%, respectively.
5 Best International Stocks To Buy For 2014: Aastrom Biosciences Inc.(ASTM)
Aastrom Biosciences, Inc., a regenerative medicine company, engages in developing autologous cell therapies for the treatment of severe and chronic cardiovascular diseases. The company?s autologous expanded cellular therapy technology uses single-pass perfusion to produce human cell products for clinical use. Its clinical development programs include CLI program, which is in phase IIb clinical development for the treatment of serious and advanced stage of peripheral arterial diseases; and DCM development program, which is in Phase II for the treatment of dilated cardiomyopathy (DCM). The company also has two ongoing U.S. Phase II trials investigating surgical and catheter-based delivery for its product in the treatment of DCM. Aastrom Biosciences, Inc. was founded in 1989 and is headquartered in Ann Arbor, Michigan.
Advisors' Opinion:- [By Roberto Pedone]
Another under-$10 biopharmaceutical player that's starting to move within range of triggering a big breakout trade is Aastrom Biosciences (ASTM), which is a regenerative medicine company focused on the development of cell therapies to repair or regenerate damaged or diseased tissues. This stock has trended modestly lower over the last three months, with shares off by 4.9%.
If you take a look at the chart for Aastrom Biosciences, you'll notice that this stock just recently formed a double bottom chart pattern at $3.16 to $3.14 a share over the last month and change. Following that bottom, shares of ASTM have started to spike higher and move back above its 50-day moving average of $3.58 a share. That move is quickly pushing shares of ASTM within range of triggering a big breakout trade.
Market players should now look for long-biased trades in ASTM if it manages to break out above some near-term overhead resistance at $4.50 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 140,540 shares. If that breakout hits soon, then ASTM will set up to re-test or possibly take out its next major overhead resistance levels at $6.25 to $6.80 a share. Any high-volume move above those levels will then give ASTM a chance to re-fill some of its previous gap-down-zone from last August that started at $12 a share.
Traders can look to buy ASTM off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average of $3.58 a share. One can also buy ASTM off strength once it starts to clear $4.50 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.
5 Best International Stocks To Buy For 2014: Goldsearch Ltd (GSE)
Goldsearch Limited (Goldsearch) is an Australia-based minerals company. During the fiscal year ended June 30, 2012 (fiscal 2012), the Company was engaged in the exploration of gold and other minerals and investment activities. It operates in five segments: Mineral Exploration Sweden, Minerals Exploration Australia-Victoria, Minerals Exploration Australia-Other, Investments and Administration. Its other projects include the Mary Kathleen joint venture in Queensland and the Musgrave joint venture in South Australia. It held 16,000 square kilometres of tenements within the Musgrave Ranges of northwestern South Australia that were in joint venture between Goldsearch and Independence Group. During fiscal 2012, the Company held investments in Morning Star Gold NL (MCO) and Musgrave Minerals Ltd (MGV). On June 30, 2012, the Company had sold off its total investment in Independence Group NL (IGO). Its subsidiaries include: Caytale Pty Limited, Chiljill Pty Limited and Miltonpak Pty Limited. Advisors' Opinion:- [By Roberto Pedone]
Another environmental services player that looks ready to trigger a near-term breakout trade is GSE Holdings (GSE), which provides geosynthetic containment solutions for environmental protection and confinement applications. This stock has been hammered by the bears so far in 2013, with shares down big by 55%.
If you take a look at the chart for GSE Holdings, you'll notice that this stock recently ripped sharply higher back above its 50-day moving average of $2.32 a share with heavy upside volume. Following that move, shares of GSE have started to trend sideways between $2.60 on the downside and $2.95 on the upside. Shares of GSE are now starting to move within range of triggering a near-term breakout trade above the upper-end of its recent range.
Traders should now look for long-biased trades in GSE if it manages to break out above some near-term overhead resistance levels at $2.79 to $2.95 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 221,545 shares. If that breakout hits soon, then GSE will set up to re-test or possibly take out its next major overhead resistance levels at $3.50 to $4 a share.
Traders can look to buy GSE off any weakness to anticipate that breakout and simply use a stop that sits right below support at $2.60 or below its 50-day moving average at $2.32 a share. One could also buy GSE off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
5 Best International Stocks To Buy For 2014: GlaxoSmithKline PLC(GSK)
GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. It offers pharmaceutical products in various therapeutic areas comprising respiratory, HIV, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, oncology and emesis, vaccines, and dermatologicals. The company provides prescription medicines to treat a range of conditions, including infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. It also markets a range of vaccines to prevent life-threatening or crippling illnesses, such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza, and bacterial meningitis. In addition, the company provides OTC medicines, including Panadol, a paracetamol-based treatment of headache and joi nt pain, fever, and cold symptoms; Gaviscon, a range of antacid products that relieve heartburn due to acid reflux; and NicoDerm, NiQuitin CQ, Nicabate, and Nicorette for the treatment of nicotine withdrawal as an aid to quit smoking. Further, it offers oral healthcare products comprising Sensodyne, a range of toothpastes and toothbrushes for the prevention of dental sensitivity; Aquafresh, a range of toothpastes, toothbrushes, and mouthwashes; and Polident, Poligrip, and Corega, which are denture adhesives and cleansers. Additionally, the company provides nutritional healthcare products consisting of Lucozade, an energy and sports drinks for energy and hydration; Horlicks, a malted, milk-based drink and food for nutrition application; and Ribena, an apple, orange, raspberry, and pomegranate flavored fruit drink, as well as markets skincare products. GlaxoSmithKline plc was incorporated in 1999 and is headquartered in Brentford, United Kingdom.
Advisors' Opinion:- [By Michael Douglass and David Williamson]
Shares of�Pernix Therapeutics� (NASDAQ: PTX ) soared 31% yesterday after the company revealed that it had bought the U.S. rights to�GlaxoSmithKline's (NYSE: GSK ) Treximet (which helps treat migraines in adults) for $250 million upfront (and some potential additional payments later). The importance of this purchase cannot easily be overstate for Pernix -- the company had $85 million in revenue last year, while Treximet on its own brought in $79 million -- and Pernix clearly sees some additional upside potential for the drug, whether it's through a potential indication expansion (to pediatric patients) or through synergies with Pernix's current salesforce.
- [By Royston Wild]
I am currently looking at the dividend prospects of�GlaxoSmithKline� (LSE: GSK ) (NYSE: GSK ) and assessing whether the company is an appetising pick for income investors.
- [By John Udovich]
On Monday after the market closed, Epizyme Inc announced the achievement of the proof of concept milestone in the EPZ-5676 DOT1L inhibitor clinical program, earning a $25 million payment under the company's collaboration with Celgene Corporation. Moreover, the European Medicines Agency's Committee for Orphan Medicinal Products has�recommended orphan drug designation for EPZ-5676 to the European Commission in December 2013 plus it was�granted orphan drug designation by the�FDA in May 2013. It was also announced in the same press release that a development candidate milestone has been achieved for one of the three histone methyltransferase (HMT) targets included in the company's collaboration with GlaxoSmithKline plc (NYSE: GSK) for another�$4 million payment.
- [By WALLSTCHEATSHEET]
GlaxoSmithKline is a health care group that engages in many aspects of the pharmaceutical business around the world. The company continues to be plagued by bribery allegations in China. The stock has moved upward in recent times and is now consolidating below highs for the year. Over the last four quarters, earnings and revenues have been decreasing. However, investors have been pleased with what they’ve heard during earnings announcements. Relative to its peers and sector, GlaxoSmithKline has been a year-to-date performance leader. WAIT AND SEE what GlaxoSmithKline does at current prices.
No comments:
Post a Comment